Testisin/Prss21 deficiency causes increased vascular permeability and a hemorrhagic phenotype during luteal angiogenesis.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2020
Historique:
received: 04 03 2020
accepted: 24 05 2020
entrez: 9 6 2020
pubmed: 9 6 2020
medline: 29 8 2020
Statut: epublish

Résumé

Testisin (encoded by PRSS21) is a membrane anchored serine protease, which is tethered to the cell surface via a glycosylphosphatidylinositol (GPI)-anchor. While testisin is found in abundance in spermatozoa, it is also expressed in microvascular endothelial cells where its function is unknown. Here we identify testisin as a novel regulator of physiological hormone-induced angiogenesis and microvascular endothelial permeability. Using a murine model of rapid physiological angiogenesis during corpus luteal development in the ovary, we found that mice genetically deficient in testisin (Prss21-/-) show a substantially increased incidence of hemorrhages which are significantly more severe than in littermate control Prss21+/+ mice. This phenotype was associated with increased vascular leakiness, demonstrated by a greater accumulation of extravasated Evans blue dye in Prss21-/- ovaries. Live cell imaging of in vitro cultured microvascular endothelial cells depleted of testisin by siRNA knockdown revealed that loss of testisin markedly impaired reorganization and tubule-like formation on Matrigel basement membranes. Moreover testisin siRNA knockdown increased the paracellular permeability to FITC-albumin across endothelial cell monolayers, which was associated with decreased expression of the adherens junction protein VE-cadherin and increased levels of phospho(Tyr658)-VE-cadherin, without affecting the levels of the tight junction proteins occludin and claudin-5, or ZO-1. Decreased expression of VE-cadherin in the neovasculature of Prss21-/- ovaries was also observed without marked differences in endothelial cell content, vascular claudin-5 expression or pericyte recruitment. Together, these data identify testisin as a novel regulator of VE-cadherin adhesions during angiogenesis and indicate a potential new target for regulating neovascular integrity and associated pathologies.

Identifiants

pubmed: 32511276
doi: 10.1371/journal.pone.0234407
pii: PONE-D-20-06406
pmc: PMC7279603
doi:

Substances chimiques

Antigens, CD 0
Cadherins 0
GPI-Linked Proteins 0
cadherin 5 0
PRSS21 protein, human EC 3.4.21.-
Prss21 protein, mouse EC 3.4.21.-
Serine Endopeptidases EC 3.4.21.-

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0234407

Subventions

Organisme : BLRD VA
ID : I01 BX001921
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA196988
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL118390
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32 HL007698
Pays : United States

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Proc Natl Acad Sci U S A. 1999 Aug 17;96(17):9815-20
pubmed: 10449777
Curr Opin Cell Biol. 2010 Oct;22(5):651-8
pubmed: 20708398
Thromb Haemost. 2003 Mar;89(3):561-72
pubmed: 12624642
Reprod Biol Endocrinol. 2003 Nov 10;1:88
pubmed: 14613536
Placenta. 2012 Oct;33(10):803-9
pubmed: 22840244
Arterioscler Thromb Vasc Biol. 2001 Jul;21(7):1104-17
pubmed: 11451738
Angiogenesis. 2008;11(2):109-19
pubmed: 18293091
Biochem Biophys Res Commun. 1999 Dec 20;266(2):564-8
pubmed: 10600542
Cancer Res. 2005 Feb 1;65(3):868-78
pubmed: 15705885
Biol Reprod. 2009 Nov;81(5):921-32
pubmed: 19571264
J Soc Gynecol Investig. 2000 Nov-Dec;7(6):358-62
pubmed: 11111072
J Cell Sci. 2008 Jul 1;121(Pt 13):2115-22
pubmed: 18565824
Blood. 2012 Mar 1;119(9):2159-70
pubmed: 22246030
Nat Cell Biol. 2006 Nov;8(11):1223-34
pubmed: 17060906
Microvasc Res. 2018 May;117:1-9
pubmed: 29247718
Biochim Biophys Acta. 2000 Jun 21;1492(1):63-71
pubmed: 11004480
Int J Dev Biol. 2011;55(3):261-8
pubmed: 21710434
Nat Cell Biol. 2008 Aug;10(8):883-5
pubmed: 18670447
J Clin Invest. 2013 Aug;123(8):3190-200
pubmed: 23908119
Cell Signal. 2003 Aug;15(8):773-81
pubmed: 12781870
Cell Adh Migr. 2013 Nov-Dec;7(6):455-61
pubmed: 24430214
J Biol Chem. 2001 Jun 8;276(23):20648-58
pubmed: 11259427
Am J Physiol Heart Circ Physiol. 2014 Aug 1;307(3):H455-63
pubmed: 24858856
Exp Cell Res. 1998 Feb 1;238(2):324-34
pubmed: 9473340
Andrology. 2019 Mar;7(2):199-212
pubmed: 30549223
Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10623-8
pubmed: 12963823
Biochim Biophys Acta. 2008 Mar;1778(3):794-809
pubmed: 17961505
Biochim Biophys Acta. 2014 Feb;1838(2):532-45
pubmed: 23899502
J Med Invest. 2003 Feb;50(1-2):78-86
pubmed: 12630572
Cancer Res. 1999 Jul 1;59(13):3199-205
pubmed: 10397266
Stroke. 2014 Mar;45(3):828-34
pubmed: 24425124
Prog Mol Biol Transl Sci. 2011;99:1-50
pubmed: 21238933
Science. 2018 Apr 20;360(6386):270-271
pubmed: 29674582
J Biol Chem. 2015 Feb 6;290(6):3529-41
pubmed: 25519908
Thromb Haemost. 2006 Jan;95(1):36-42
pubmed: 16543959
Sci Rep. 2014 Oct 10;4:6588
pubmed: 25300427
Br J Cancer. 2005 Feb 28;92(4):760-9
pubmed: 15685234
J Cell Biochem. 2017 Dec;118(12):4587-4593
pubmed: 28485540
J Mol Med (Berl). 2019 May;97(5):691-709
pubmed: 30911775
Cytokine Growth Factor Rev. 1997 Mar;8(1):21-43
pubmed: 9174661
Nat Commun. 2012;3:1208
pubmed: 23169049
Genes Cells. 2008 Oct;13(10):1001-13
pubmed: 18754795
Endothelium. 2001;8(3):221-34
pubmed: 11824474
Annu Rev Cell Dev Biol. 2011;27:213-35
pubmed: 21721945
Proc Natl Acad Sci U S A. 2008 Jul 22;105(29):10185-90
pubmed: 18632559
J Immunol. 2007 Sep 15;179(6):4053-64
pubmed: 17785844
Nat Commun. 2017 Dec 20;8(1):2210
pubmed: 29263363
J Cell Biol. 2003 Sep 15;162(6):1111-22
pubmed: 12975353
Annu Rev Pathol. 2016 May 23;11:251-81
pubmed: 26907525
Exp Cell Res. 2006 Mar 10;312(5):608-22
pubmed: 16442099
J Biol Chem. 2005 Sep 9;280(36):31906-12
pubmed: 16027153
Nat Rev Mol Cell Biol. 2007 Jun;8(6):464-78
pubmed: 17522591
J Invest Dermatol. 1992 Dec;99(6):683-90
pubmed: 1361507

Auteurs

Raymond J Peroutka (RJ)

Department of Physiology, Center for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore, Maryland, United Sates of America.

Marguerite S Buzza (MS)

Department of Physiology, Center for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore, Maryland, United Sates of America.
VA Maryland Health Care System, Baltimore, Maryland, United Sates of America.
Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland, United Sates of America.

Subhradip Mukhopadhyay (S)

Department of Physiology, Center for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore, Maryland, United Sates of America.
VA Maryland Health Care System, Baltimore, Maryland, United Sates of America.
Department of Surgery, University of Maryland School of Medicine, Baltimore, Maryland, United Sates of America.

Tierra A Johnson (TA)

Department of Physiology, Center for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore, Maryland, United Sates of America.
VA Maryland Health Care System, Baltimore, Maryland, United Sates of America.

Kathryn H Driesbaugh (KH)

Department of Physiology, Center for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore, Maryland, United Sates of America.

Toni M Antalis (TM)

Department of Physiology, Center for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore, Maryland, United Sates of America.
VA Maryland Health Care System, Baltimore, Maryland, United Sates of America.
Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland, United Sates of America.
Department of Surgery, University of Maryland School of Medicine, Baltimore, Maryland, United Sates of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH